Efficacy of Infliximab as a Secondary Treatment for Kawasaki Disease Resistant to IVIG
Overview
This study evaluates the efficacy of infliximab as a second-line treatment for Kawasaki disease (KD) patients resistant to intravenous immunoglobulin (IVIG). Results indicate that infliximab significantly reduces fever duration compared to additional IVIG, highlighting its potential as a more effective alternative.
Background
Kawasaki disease is a significant cause of acquired heart disease in children, with a notable percentage of patients being resistant to standard IVIG therapy. These resistant cases are at increased risk for serious complications, including coronary artery abnormalities. Identifying effective second-line treatments is crucial for improving outcomes in this vulnerable population.
Data Highlights
No numerical data available in the provided material.
Key Findings
Approximately 20% of KD patients are resistant to initial IVIG treatment.
Infliximab has been shown to induce rapid defervescence in KD patients.
The time to fever resolution was significantly shorter in the infliximab group compared to the additional IVIG group.
Clinical subgroups suitable for infliximab or additional IVIG were identified using laboratory factors.
Infliximab carries potential adverse effects, including an increased risk of serious infections.
Clinical Implications
Clinicians should consider infliximab as a viable second-line treatment option for KD patients who do not respond to IVIG. Individualized treatment plans based on clinical and laboratory factors may enhance therapeutic outcomes and minimize risks.
Conclusion
Infliximab presents a promising alternative to additional IVIG for treating IVIG-resistant Kawasaki disease, with evidence supporting its efficacy in reducing fever duration. Further studies are warranted to refine treatment strategies for this condition.
